Redx Pharma begins next study for RXC004
Redx Pharma
15.00p
16:55 30/04/24
31.58%
3.60p
Drug discovery and development company Redx Pharma announced on Tuesday that it has commenced its Phase 1/2a study for the Porcupine inhibitor RXC004, with the first patient having now been dosed at The Christie in Manchester.
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
-2.70%
-535.19